EDP Sciences logo
Search
Menu
All issues Volume 35 / No 4 (July-August 2004) Vet. Res., 35 4 (2004) 425-443 References
Free Access
Issue
Vet. Res.
Volume 35, Number 4, July-August 2004
Equine infectious diseases
Page(s) 425 - 443
DOI https://doi.org/10.1051/vetres:2004019
How to cite this article Vet. Res. (2004) 425-443
References of Vet. Res. 35 425-443
  1. Allen G.P., Bryans J.T., Molecular epizootiology, pathogenesis and prophylaxis of equine herpesvirus-1 infections, Prog. Vet. Microbiol. Immunol. 2 (1986) 78-144 [PubMed].
  2. Allen G.P., Kydd J.H., Slater J.D., Smith K.C., Advances in understanding of the pathogenesis, epidemiology and immunological control of equine herpesvirus abortion, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious diseases VIII, R&W Publications Ltd, Newmarket, 1998, p. 129.
  3. Allen G.P., Yeragan M.R., Turtinen L.W., Bryans J.T., A new field strain of equine abortion virus (equine herpesvirus-1) among Kentucky horses, Am. J. Vet. Res. 46 (1985) 138-140 [PubMed].
  4. Audonnet J.C., Mumford J.A., Jessett D.M., Pardo M.C., Taylor J., Tartaglia J., Minke J.M., Safety and efficacy of a canarypox-EHV recombinant in horses, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious diseases VIII, R&W Publications Ltd, Newmarket, 1998, pp. 418-419.
  5. Balasuriya U.B., Heidner H.W., Davis N.L., Wagner H.M., Hullinger P.J., Hedges J.F., Williams J.C., Johnston R.E., Wilson W.D, Liu I.K., MacLachlan N.J., Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses, Vaccine 20 (2002) 1609-1617 [CrossRef] [PubMed].
  6. Bennett A.M., Lescott T., Phillpotts R.J., Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus, Viral Immunol. 11 (1998) 109-117 [PubMed].
  7. Berge T.O., Banks I.S., Tigertt W.D., Attenuation of Venezuelan equine encephalomyelitis vaccine by in vitro cultivation in guinea-pig heart cells, Am. J. Hyg. 73 (1961) 209-218.
  8. Bowen R.A., Short W.A., Cropp C.B., Mathews J.H., Roehrig J.T., Kinney R.M., DeMartini J.C., Trent D.W., Protection of horses immunized with recombinant vaccinea-Venezuelan Equine encephalitis vaccine, Vaccine Res. 1 (1992) 111-121.
  9. Bryans J.T., Doll E.R., Wilson J.C., McCollum W.H., Immunisation for equine influenza, J. Am. Vet. Med. Assoc. 148 (1966) 413-417 [PubMed].
  10. Bunning M.L., Bowen R.A., Cropp C.B., Sullivan K.G., Davis B.S., Komar N., Godsey M.S., Baker D., Hettler D.L., Holmes D.A., Biggerstaff B.J., Mitchell C.J., Experimental infection of horses with West Nile virus, Emerg. Infect. Dis. 8 (2002) 380-386 [PubMed].
  11. Bürki F., Nowotny N., Oulehla J., Schmehlik O., Möstl K., Pallan C., Rossmanith E., Attempts to immunoprotect adult horses, specifically pregnant mares, with commercial vaccines against clinical disease induced by equine herpesvirus-1, J. Vet. Med. 38 (1991) 432-440.
  12. Bürki F., Rossmanith W., Nowotny N., Pallan C., Möstl K., Lussy H., Viraemia and abortions are not prevented by two commercial Equine herpesvirus 1 vaccines after experimental challenge of horses, Vet. Q. 12 (1990) 80-86 [PubMed].
  13. Burrows R., Goodridge D., Equid herpesvirus 1 (EHV-1): some observations on the epizootiology of infection and on the innocuity testing of live virus vaccines, in: Proc. 24th Annu. Conf. Am. Ass. Equine Practitioners, St. Louis, 1978, pp. 17-29.
  14. Burrows R., Goodridge D., Denyer M.S., Trials of an inactivated equid herpes virus vaccine: challenge with a subtype 1 virus, Vet. Rec. 114 (1984) 369-374 [PubMed].
  15. Calisher C.H., Monath T.P., Mitchell C.J., Sabatinni M.S., Cropp C.B., Kerschner J., Hunt A.R., Lazuick J.S., Arbovirus investigations in Argentina, 1977-1980. III. Identification and characterization of viruses isolated, including new subtypes of Western and Venezuelan equine encephalitis viruses and four new bunyaviruses (Las Maloyas, Resistencia, Barranqueras and Antequera), Am. J. Trop. Med. Hyg. 34 (1985) 956-965 [PubMed].
  16. Castillo-Olivares J., de Vries A.A., Raamsman M.J., Rottier P.J., Lakani K., Westcott D., Tearle J.P., Wood J.L., Mumford J.A., Hannant D., Davis-Poynter N.J., Evaluation of a prototype sub-unit vaccine against equine arteritis virus comprising the entire ectodomain of the virus envelope glycoprotein (GL): induction of virus neutralising antibody and assessment of protection in ponies, J. Gen. Virol. 82 (2001) 2425-2435 [PubMed].
  17. Castillo-Olivares J., Wieringa R., Bakonyi T., de Vries A.A., Davis-Poynter N.J., Rottier P.J., Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain, J. Virol. 77 (2003) 8470-8480 [CrossRef] [PubMed].
  18. Chambers T.M., Holland R.E., Tudor L.R., Townsend H.G., Cook A., Bogdan J., Lunn D.P., Hussey S., Whitaker-Dowling P., Youngner J.S., Sebring R.W., Penner S.J., Stiegler G.L., A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge, Equine Vet. J. 33 (2001) 630-636 [PubMed].
  19. Chirnside E.D., Francis P.M., Mumford J.A., Expression cloning and antigenic analysis of the nucleocapsid protein of equine arteritis virus, Virus Res. 39 (1995) 277-288 [CrossRef] [PubMed].
  20. Cullinane A., Weld J., Osborne M., Nelly M., McBride C., Walsh C., Field studies on equine influenza vaccination regimes in thoroughbred foals and yearlings, Vet. J. 161 (2001) 174-185 [CrossRef] [PubMed].
  21. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., Bowen R.A., Bunning M.L., West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a non-infectious recombinant antigen that can be used in enzyme-linked immunosorbent assays, J. Virol. 9 ( 2001) 4040-4047.
  22. Davis N.L., Willis L.V., Smith J.F., Johnston R.E., In vitro synthesis of infectious Venezuelan encephalitis virus RNA from a cDNA clone. Analysis of a viable deletion mutant, Virology 171 (1989) 189-204 [CrossRef] [PubMed].
  23. Doll E.R., Immunization against viral rhinopneumonitis of horses with live virus propagated in hamsters, J. Biochem. 139 (1961) 1324-1330 [PubMed].
  24. Doll E.R., Bryans J.T., Immunization of young horses against viral rhinopneumonitis, Cornell Vet. 53 (1963) 24-41 [PubMed].
  25. Doll E.R., Bryans J.T., McCollum W.H., A procedure for evaluating the antigenicity of killed virus vaccines for equine rhinopneumonitis, Cornell Vet. 49 (1959) 212-220 [PubMed].
  26. Eddy G.A., Martin D.H., Reeves W.C., Johnston K.M., Field studies of an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83), Infect. Immun. 5 (1972) 160-163 [PubMed].
  27. Ferguson J.A., Reeves W.C., Milby M.M., Hardy J.L., Study of homologous and heterologous antibody response in California horses vaccinated with attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83), Am. J. Vet. Res. 39 (1978) 371-376 [PubMed].
  28. Fischer J., Barzu S., Andreoni C., Buisson N., Brun A., Audonnet J.C., DNA vaccination of neonate piglets in the face of maternal immunity induces humoral memory and protection against a virulent pseudorabies virus challenge, Vaccine 21 (2003) 1732-1741 [CrossRef] [PubMed].
  29. Fischer L., Minke J., Dufay N., Baudu Ph., Audonnet J.C., Rabies DNA vaccine in the horse: strategies to improve serological responses, Vaccine 21 (2003) 4593-4596 [CrossRef] [PubMed].
  30. Fitzpatrick D.R., Studdert M.J., Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus), Am. J. Vet. Res. 45 (1984) 1947-1952 [PubMed].
  31. Franck P., Round table on epidemic control, in: Venezuelan encephalitis (Scientific Publication No. 243), Washington, Pan American Health Organisation, 1972, pp. 400-401.
  32. Franklin R.P., Kinde H., Jay M.T., Kramer L.D., Green E.G., Chiles R.E., Ostlund E., Husted S., Smith J., Parker M.D., Eastern equine encephalomyelitis virus infections in a horse from California, Emerg. Infect. Dis. 8 (2002) 283-288 [PubMed].
  33. Fukunaga Y., Wada R., Hirasawa K., Kamada M., Kunanomido T., Akiyama Y., Effect of the modified Bucyrus strain of equine arteritis virus experimentally inoculated into horses, Bull. Equine Res. Inst. 19 (1982) 97-101.
  34. Fukunaga Y., Wada R., Matsumura T., Sugiura T., Imagawa H., Induction of immune response and protection from equine viral arteritis (EVA) by formalin inactivated-virus vaccine for EVA in horses, J. Vet. Med. B 37 (1990) 135-141.
  35. Fukunaga Y., Wada R., Kanemaru T., Imagawa H., Kamada M., Samejima T., Immune potency of lyophilised, killed vaccine for equine viral arteritis and its protection against abortion in pregnant mares, J. Equine Vet. Sci. 16 (1996) 217-221.
  36. Fukunaga Y., Wada R., Imagawa H., Kanemaru T., Venereal infection of mares by equine arteritis virus and use of killed vaccine against the infection, J. Comp. Pathol. 117 (1997) 201-208 [PubMed].
  37. Glaser A.L., de Vries A.A., Raamsman M.J., Horzinek M.C., Rottier P.J., An infectious clone of equine arteritis virus: a tool for future fundamental studies and vaccine development, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious diseases VIII, R&W Publications Ltd, Newmarket, 1998, pp. 166-176.
  38. Hannant D., Mumford J.A., Cell mediated immune responses in ponies following infection with equine influenza virus (H3N8): the influence of induction culture conditions on the properties of cytotoxic effector cells, Vet. Immunol. Immunopathol. 21 (1989) 327-337 [PubMed].
  39. Hannant D., Easeman R., Mumford J.A., Equine mucosal immune system: intranasal vaccination with inactivated influenza virus protects from infection, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious diseases VIII, R&W Publications Ltd, Newmarket, 1998, pp. 50-56.
  40. Heldens J.G., Hannant D., Cullinane A.A., Prendergast M.J., Mumford J.A., Nelly M., Kydd J.H., Weststrate M.W., van der Hoven R., Clinical and virological evaluation of the efficacy of an inactivated EHV1and EHV4 whole virus vaccine (Duvaxyn EHV1,4). Vaccination/challenge experiments in foals and pregnant mares, Vaccine 19 (2001) 97-114.
  41. Heldens J.G., Kersten A.J., Weststrate M.W., van den Hoven R., Duration of immunity induced by an adjuvanted and inactivated equine influenza, tetanus and equine herpes 1 and 4 combination vaccine, Vet. Q. 23 (2001) 210-217 [PubMed].
  42. Hodgson L.A., Ludwig G.V., Smith J.F., Expression, processing and immunogenicity of structural proteins of Venezuelan encephalitis virus from recombinant baculovirus, Vaccine 17 (1999) 1151-1160 [CrossRef] [PubMed].
  43. Hoke C.H., Nisalak A., Sangawhipa N., Jatanasen S., Laorakapongse T., Innis B.L., Kotchasenee S., Gingrich J.B., Latendresse J., Fukai K., Burke D.S., Protection against Japanese encephalitis by inactivated vaccines, N. Engl. J. Med. 319 (1988) 608-614 [PubMed].
  44. Jessett D.M., Schrag D., Mumford J.A., Protection by an attenuated EHV-1 vaccine against challenge with a virulent EHV-1 AB4 isolate, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious Diseases VIII, R&W Publications Ltd, Newmarket, 1998, pp. 414-415.
  45. Kanesa-thasan N., Smucny J.J., Hoke C.H., Marks D.H., Konishi E., Kurane I., Tang D.B., Vaughn D.W., Mason P.W., Shope R.E., Safety and immunogenicity of NYCAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus - poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans, Vaccine 19 (2001) 483-491.
  46. Kinney R.M., Esposito J.J., Mathews J.H., Johnson B.J., Roehrig J.T., Barrett A.D., Trent D.W., Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge, J. Virol. 62 (1988) 4697-4702 [PubMed].
  47. Kinney R.M., Tsuchiya K.R., Sneider J.M., Trent D.W., Molecular evidence for the origin of the widespread Venezuelan encephalitis epizootic of 1969 to 1972, J. Gen. Virol. 73 (1992) 3301-3305 [PubMed].
  48. Klein N., Duration of immunity, in: Mumford J.A., Daly J.M., Wade J.F. (Eds.), Proceedings of Fourth International Meeting of OIE and WHO Experts on Control of Equine Influenza, Miami, USA, R&W Publications Ltd, Newmarket, 2003, pp. 36-37.
  49. Konishi E., Pincus S., Paoletti E., Laegreid W.W., Shope R.E., Mason P., A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine, Virology 190 (1992) 454-458 [CrossRef] [PubMed].
  50. Konishi E., Kurane I., Mason P., Shope R.E., Ennis F.A., Pox virus-based Japanese encephalitis vaccine candidates induced JE virus-specific CD8+ cytotoxic lymphocytes in mice, Virology 227 (1997) 353-360 [CrossRef] [PubMed].
  51. Liu I.K.M., Castleman W., Equine posterior paresis associated with equine herpesvirus 1 vaccine in California: a preliminary report, J. Equine Med. Surg. 1 (1977) 397-401.
  52. Luedke A.J., Barber T.L., Foster N.M., Batalla D., Mercado S., Effect of back passage of Venezuelan equine encephalomyelitis TC-83 vaccine virus on clinical, virologic and immune responses in horses, J. Am. Vet. Med. Assoc. 161 (1972) 824-831.
  53. Lunn D.P., Soboll G., Schramm B.R., Quass J., McGregor M.W., Drape R.J., Macklin M.D., McCabe D.E., Swain W.F., Olsen C.W., Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene, Vaccine 17 (1999) 2245-2258 [CrossRef] [PubMed].
  54. Matsumura T., Kondo T., Sugita S., Damiani A.M., O'Callaghan D.J., Imagawa H., An equine herpesvirus type 1 recombinant with a deletion in the gE gene and gI genes is avirulent in young horses, Virology 242 (1998) 68-79 [CrossRef] [PubMed].
  55. Mayr A., Pette J., Petzoldt K., Wagener K., Untersuchungen zur Entwicklung eines Lebendimstofstoffes gegen die Rhinopneumonitis (stutenabort) der Pferde, Zentralbl. Veterinaermed. B 15 (1968) 406-418.
  56. McCollum W.H., Development of a modified virus strain and vaccine for equine viral arteritis, J. Am. Vet. Med. Assoc. 155 (1969) 318-322 [PubMed].
  57. McGuire T.C., Tumas D.B., Hines M.T., Leib S.R., Brassfield A.L., O'Rourke K.I., Perryman L.E., Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins, J. Virol. 68 (1994) 1459-1467 [PubMed].
  58. McKinnon A.O., Colbern G.T., Collins J.K., Bowen R.A., Voss J.L., Umphenour J.W., Vaccination of stallions with a modified live equine viral arteritis virus, J. Equine Vet. Sci. 6 (1986) 66-69.
  59. Mellencamp M., Schultze A., Development of an inactivated equine influenza vaccine to meet global requirements, in: Proceedings Quality Control of Equine Influenza Vaccines, Budapest, 2001, pp. 79-81.
  60. Minke J.M., Flore P.H., Vaarten J., Vandehoek J., Weststrate M., An inactivated EHV-1 and EHV-4 containing vaccine reduces clinical signs in horses infected experimentally with EHV-1 or EHV-4 six months after a single vaccination, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious diseases VIII, R&W Publications Ltd, Newmarket, 1998, pp. 564-565.
  61. Minke J.M., Audonnet J.C., Jessett D.M., Fischer L., Guigal P.M., Coupier H., Pardo M.C., Taylor J., Tartaglia J., Mumford J.A., Canarypox as vector for influenza and EHV-1 genes: challenges and rewards, in: 2nd International Veterinary Vaccines and Diagnostics Conference, Oxford, 2000, p.36.
  62. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., Renshaw R.W., Loosmoore S., Audonnet J.C., Nordgren B., Recombinant canarypox virus carrying the preM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge, Arch. Virol. Suppl. 18 (2004) 221-230 [PubMed].
  63. Morley P.S., Townsend H.G., Bogdan J.R., Haines D.M., Risk factors for disease associated with influenza virus infections during three epidemics in horses, J. Am. Vet. Med. Assoc. 216 (2000) 545-550 [PubMed].
  64. Mumford J.A., Control of influenza from an international perspective, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious diseases VIII, R&W Publications Ltd, Newmarket, 1998, pp. 11-24.
  65. Mumford J.A., Wood J., Establishing an acceptable threshold for equine influenza vaccines, Dev. Biol. Stand. 79 (1992) 137-146 [PubMed].
  66. Mumford J.A., Hannant D., Jessett D.M., O'Neill T., Evaluation of protective efficacy of equid herpesvirus type 1 ISCOM vaccine for the abortigenic form of disease, J. Reprod. Fertil. 44 Suppl. (1991) 730-731.
  67. Mumford J.A., Jessett D.M., Rollinson E.A., Hannant D., Draper M.E., Duration of protective efficacy in equine influenza immunostimulating complex/tetanus vaccines, Vet. Rec. 134 (1994) 158-162 [PubMed].
  68. Mumford J.A., Wilson H., Hannant D., Jessett D.M., Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant, Epidemiol. Infect. 112 (1994) 421-437 [PubMed].
  69. Nelson K.M., Schram B.R., McGregor M.W., Sheoran A.S., Olsen C.W., Lunn D.P., Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination, Vaccine 16 (1998) 1306-1313 [CrossRef] [PubMed].
  70. Neubauer A., Meindl A., Osterrieder N., Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation, Berl. Muench. Tieraerztl. Wochenschr. 112 (1999) 351-354.
  71. Nugent J., Sinclair R., de Vries A.A., Eberhardt R.Y., Castillo-Olivares J., Davis-Poynter N., Rottier P.J., Mumford J.A., Development and evaluation of ELISA procedures to detect antibodies against the major envelope protein (GL) of equine arteritis virus, J. Virol. Methods 90 (2000) 167-183 [CrossRef] [PubMed].
  72. Oberste M.S., Fraire M., Navarro R., Zepeda C., Zarate M.L., Ludwig G.V., Kondig J.F., Weaver S.C., Smith J.F., Rico-Hesse R., Association of Venezuelan equine encephalitis virus subtype IE with two equine epizootics in Mexico, Am. J. Trop. Med. Hyg. 59 (1998) 100-107 [PubMed].
  73. Paessler S., Fayzulin R.Z., Anishchenko M., Greene I.P., Weaver S.C., Frolov I., Recombinant Sindbis/VEE virus is highly attenuated and immunogenic, J. Virol. 77 (2003) 9278-9286 [CrossRef] [PubMed].
  74. Palfi V., Christensen L.S., Analyses of restriction fragment (RFPs) and pathogenicity in baby mice of equine herpesvirus 1 and 4 (EHV-1 and EHV-4) strains circulating in Danish horses, Vet. Microbiol. 47 (1995) 199-204 [CrossRef] [PubMed].
  75. Pardo M.C., Bauman J.E., Mackowiak M., Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins, Am. J. Vet. Res. 58 (1997) 833-836 [PubMed].
  76. Patel J.R., Földi J., Bateman H., Williams J., Didlick S., Stark R., Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory disease following EHV types 1 and 4 challenges, Vet. Microbiol. 92 (2003) 1-17 [CrossRef] [PubMed].
  77. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J., Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine, Vaccine 14 (1996) 337-343 [CrossRef] [PubMed].
  78. Plotkin S.A., Cadoz M., Meignier B., Meric C., Leroy O., Excler J.L., Tartaglia J., Paoleti E., Gonczol E., Chappuis G., The safety and use of canarypox vectored vaccines, Dev. Biol. Stand. 84 (1995) 165-170 [PubMed].
  79. Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., Minke J., Audonnet J.C., Desmettre P., Efficacy of a canarypox virus-vectored vaccine against feline leukaemia, Vet. Rec. 153 (2003) 141-145 [PubMed].
  80. Powell D.G., Short review: Epidemiology and control of equine viral disease, in: Studdert M.J. (Ed.), Virus infections of Vertebrates 6, Elsevier, Amsterdam, 1996, pp. 327-339.
  81. Pratt W.D., Davis N.L., Johnston R.E., Smith J.F., Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models, Vaccine 21 (2003) 3854-3862 [CrossRef] [PubMed].
  82. Research Committee for prevention of stillbirth in sows due to Japanese encephalitis, Bull. Natl. Inst. Anim. Health 57 (1968) 1-8.
  83. Robinson H.L., DNA vaccines: basic mechanism and immune responses, Int. J. Mol. Med. 4 (1999) 549-555 [PubMed].
  84. Schoepp R.J., Smith J.F., Parker M.D., Recombinant chimeric Western and Eastern Encephalitis viruses as potential vaccine candidates, Virology 302 (2002) 299-309 [CrossRef] [PubMed].
  85. Siegrist C.A., Saddallah F., Tougne C., Martinez X., Kovarik J., Lamber P.H., Induction of neonatal TH1 and CTL responses by live viral vaccines: a role for replication patterns within antigen presenting cells, Vaccine 16 (1998) 1473-1478 [CrossRef] [PubMed].
  86. Slater J.D., Gibson J.S., Field H.J., Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals, J. Gen. Virol. 74 (1993) 819-828 [PubMed].
  87. Soboll G., Whalley J.M., Koen M.T., Allen G.P., Fraser D.G., Macklin M.D., Swain W.F., Lunn D.P., Identification of equine herpesvirus-1 antigens recognized by cytotoxic T lymphocytes, J. Gen. Virol. 84 (2003) 2625-2634 [CrossRef] [PubMed].
  88. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., Paoletti E., Efficacy studies on a canarypox-rabies recombinant virus, Vaccine 9 (1991) 190-193 [CrossRef] [PubMed].
  89. Tewari D., Gibson J.S., Slater J.D., O'Neill T., Hannant D., Allen G.P., Field H.J., Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection to EHV-4 or a TK-deletion mutant of EHV-1, Arch. Virol. 132 (1993) 101-120 [PubMed].
  90. Thomson G.R., Mumford J.A., Smith I.M., Experimental immunization against respiratory disease due to equine herpesvirus 1 infection (rhinopneumonitis) using formalin-inactivated virus with various adjuvants, Vet. Microbiol. 4 (1979) 209-222 [CrossRef].
  91. Timoney P.J., McCollum W.H., Equine viral arteritis: epidemiology and control, J. Equine Vet. Sci. 8 (1988) 54-59.
  92. Townsend H.G., Penner S.J., Watts T.C., Cook A., Bogdan J., Haines D.M., Griffin S., Chambers T., Holland R.E., Whitaker-Dowling P., Younger J.S., Sebring R.W., Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials, Equine Vet. J. 33 (2001) 637-643 [PubMed].
  93. Van Maanen C., Equine herpes virus 1 and 4 infections: an update, Vet. Q. 24 (2002) 57-78.
  94. Van Maanen C., Bruin G., de Boer-Luytze E., Smolders G., De Boer G.F., Interference of maternal antibodies with the immune response of foals after vaccination against equine influenza, Vet. Q. 14 (1992) 13-17 [PubMed].
  95. Van Oirschot J.T., Present and future of veterinary viral vaccinology: a review, Vet. Q. 23 (2001) 100-108 [PubMed].
  96. Van Oirschot J., Bruin G., De Boer-Luytze E., Smolders G., Maternal antibodies against equine influenza virus in foals and their interference with vaccination, J. Vet. Med. 38 (1991) 391-396.
  97. Walton T.E., Brantigam F.E., Ferrer J.A., Johnson K.M., Epizootic Venezuelan equine encephalomyelitis in Central America. Disease pattern and vaccine evaluation in Nicaragua, 1969-1970, Am. J. Epidemiol. 95 (1972) 247-254 [PubMed].
  98. Walton T.E., Alvarez O., Buckwalter R.M., Johnson K.M., Experimental infection of horses with an attenuated Venezuelan equine encephalitis vaccine (strain TC-83), J. Infect. Dis. 128 (1973) 271-282 [PubMed].
  99. Webster R.G., Are equine 1 influenza viruses still present in horses ? Equine Vet. J. 25 (1993) 537-539 [PubMed].
  100. Whalen J.W., Hall V.L., Srinivasappa J., Ross C., Eichmeyer M., Chu S., An inactivated vaccine prevents persistent equine arteritis virus infection in stallions, in: Wernery U., Wade J.F., Mumford J.A., Kaaden O.R. (Eds.), Equine Infectious diseases VIII, R&W Publications Ltd, Newmarket, 1998, p. 595.
  101. Xin Y.Y., Ming Z.G., Peng G.Y., Jian A., Min L.H., Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children, Am. J. Trop. Med. Hyg. 39 (1988) 214-217 [PubMed].
  102. Yates P., Mumford J.A., Equine influenza vaccine efficacy: the significance of antigenic variation, Vet. Microbiol. 74 (2000) 173-177 [CrossRef] [PubMed].